These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25495260)

  • 21. Alzheimer's drug update. Harvard researchers help test new drugs that could strike at the root of Alzheimer's disease. Here's where things stand.
    Harv Mens Health Watch; 2013 Jan; 17(6):6-7. PubMed ID: 23819191
    [No Abstract]   [Full Text] [Related]  

  • 22. New and emerging treatments for Alzheimer's disease.
    Corbett A; Smith J; Ballard C
    Expert Rev Neurother; 2012 May; 12(5):535-43. PubMed ID: 22550982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging amyloid disease-modifying drugs for Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Emerg Drugs; 2016; 21(1):5-7. PubMed ID: 26817686
    [No Abstract]   [Full Text] [Related]  

  • 25. Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012).
    Belluti F; Rampa A; Gobbi S; Bisi A
    Expert Opin Ther Pat; 2013 May; 23(5):581-96. PubMed ID: 23425062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current therapeutic strategy in Alzheimer's disease.
    Singh S; Kushwah AS; Singh R; Farswan M; Kaur R
    Eur Rev Med Pharmacol Sci; 2012 Nov; 16(12):1651-64. PubMed ID: 23161037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Alzheimer's disease therapeutics.
    Rafii MS
    J Alzheimers Dis; 2014; 42 Suppl 4():S545-9. PubMed ID: 25079804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
    Saxena U
    Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neurobiology and molecular biology of Alzheimer's disease].
    DeKosky ST
    Rev Neurol; 2002 Oct 16-31; 35(8):752-60. PubMed ID: 12402229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms.
    Giuliani D; Ottani A; Zaffe D; Galantucci M; Strinati F; Lodi R; Guarini S
    Neurobiol Learn Mem; 2013 Sep; 104():82-91. PubMed ID: 23726868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advances in study on the pharmacological effects of active components of Chinese herbs on Alzheimer's disease].
    Wu L; Cheng SY; Wang Q; Chen YB
    Zhongguo Zhong Yao Za Zhi; 2004 May; 29(5):387-9. PubMed ID: 15706882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug therapy of Alzheimer's disease. Problems and strategy in development of new therapeutic drugs for Alzheimer's disease].
    Moroji T; Matsuzaki I
    Nihon Rinsho; 1988 Jul; 46(7):1586-91. PubMed ID: 2906096
    [No Abstract]   [Full Text] [Related]  

  • 34. Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease.
    Camargo LC; Campos GAA; Galante P; Biolchi AM; Gonçalves JC; Lopes KS; Mortari MR
    Neuropeptides; 2018 Feb; 67():79-86. PubMed ID: 29198480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient four-drug cocktail therapy targeting amyloid-β peptide for Alzheimer's disease.
    Asai M; Iwata N; Tomita T; Iwatsubo T; Ishiura S; Saido TC; Maruyama K
    J Neurosci Res; 2010 Dec; 88(16):3588-97. PubMed ID: 20890992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coxibs and Alzheimer's disease: should they stay or should they go?
    Firuzi O; Praticò D
    Ann Neurol; 2006 Feb; 59(2):219-28. PubMed ID: 16402383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reserpine modulates neurotransmitter release to extend lifespan and alleviate age-dependent Aβ proteotoxicity in Caenorhabditis elegans.
    Saharia K; Arya U; Kumar R; Sahu R; Das CK; Gupta K; Dwivedi H; Subramaniam JR
    Exp Gerontol; 2012 Feb; 47(2):188-97. PubMed ID: 22212533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid metabolism and Alzheimer's disease: pathways and possibilities.
    Saxena U
    Expert Opin Ther Targets; 2009 Mar; 13(3):331-8. PubMed ID: 19236155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.